175 related articles for article (PubMed ID: 35671983)
1. Stealth oxime ether lipid vesicles promote delivery of functional DsiRNA in human lung cancer A549 tumor bearing mouse xenografts.
Puri A; Ibrahim F; O'Reilly Beringhs A; Isemann C; Zakrevsky P; Whittenburg A; Hargrove D; Kanai T; Dillard RS; de Val N; Nantz MH; Lu X; Shapiro BA
Nanomedicine; 2022 Aug; 44():102572. PubMed ID: 35671983
[TBL] [Abstract][Full Text] [Related]
2. Oxime ether lipids containing hydroxylated head groups are more superior siRNA delivery agents than their nonhydroxylated counterparts.
Gupta K; Mattingly SJ; Knipp RJ; Afonin KA; Viard M; Bergman JT; Stepler M; Nantz MH; Puri A; Shapiro BA
Nanomedicine (Lond); 2015; 10(18):2805-18. PubMed ID: 26107486
[TBL] [Abstract][Full Text] [Related]
3. Oxime Ether Lipids as Transfection Agents: Assembly and Complexation with siRNA.
Puri A; Zampino S; Viard M; Shapiro BA
Methods Mol Biol; 2017; 1632():241-253. PubMed ID: 28730444
[TBL] [Abstract][Full Text] [Related]
4. Hydrophobic oxime ethers: a versatile class of pDNA and siRNA transfection lipids.
Biswas S; Knipp RJ; Gordon LE; Nandula SR; Gorr SU; Clark GJ; Nantz MH
ChemMedChem; 2011 Nov; 6(11):2063-9. PubMed ID: 21882348
[TBL] [Abstract][Full Text] [Related]
5. The Effect of Dicer Knockout on RNA Interference Using Various Dicer Substrate Small Interfering RNA (DsiRNA) Structures.
Song MS; Alluin J; Rossi JJ
Genes (Basel); 2022 Feb; 13(3):. PubMed ID: 35327991
[TBL] [Abstract][Full Text] [Related]
6. Amino-modified and lipid-conjugated dicer-substrate siRNA enhances RNAi efficacy.
Kubo T; Takei Y; Mihara K; Yanagihara K; Seyama T
Bioconjug Chem; 2012 Feb; 23(2):164-73. PubMed ID: 22236254
[TBL] [Abstract][Full Text] [Related]
7. Systemic delivery of stable siRNA-encapsulating lipid vesicles: optimization, biodistribution, and tumor suppression.
Dar GH; Gopal V; Rao NM
Mol Pharm; 2015 Feb; 12(2):610-20. PubMed ID: 25545110
[TBL] [Abstract][Full Text] [Related]
8. In vivo activation of PEGylated long circulating lipid nanoparticle to achieve efficient siRNA delivery and target gene knock down in solid tumors.
Sasayama Y; Hasegawa M; Taguchi E; Kubota K; Kuboyama T; Naoi T; Yabuuchi H; Shimai N; Asano M; Tokunaga A; Ishii T; Enokizono J
J Control Release; 2019 Oct; 311-312():245-256. PubMed ID: 31505222
[TBL] [Abstract][Full Text] [Related]
9. Poly(ethylene glycol)-block-poly(ε-caprolactone)-and phospholipid-based stealth nanoparticles with enhanced therapeutic efficacy on murine breast cancer by improved intracellular drug delivery.
He X; Li L; Su H; Zhou D; Song H; Wang L; Jiang X
Int J Nanomedicine; 2015; 10():1791-804. PubMed ID: 25784805
[TBL] [Abstract][Full Text] [Related]
10. Poly(vinyl pyrrolidone) derivatives as PEG alternatives for stealth, non-toxic and less immunogenic siRNA-containing lipoplex delivery.
Berger M; Toussaint F; Djemaa SB; Laloy J; Pendeville H; Evrard B; Jerôme C; Lechanteur A; Mottet D; Debuigne A; Piel G
J Control Release; 2023 Sep; 361():87-101. PubMed ID: 37482343
[TBL] [Abstract][Full Text] [Related]
11. RGD-based active targeting of novel polycation liposomes bearing siRNA for cancer treatment.
Yonenaga N; Kenjo E; Asai T; Tsuruta A; Shimizu K; Dewa T; Nango M; Oku N
J Control Release; 2012 Jun; 160(2):177-81. PubMed ID: 22019557
[TBL] [Abstract][Full Text] [Related]
12. Nanoparticles evading the reticuloendothelial system: role of the supported bilayer.
Li SD; Huang L
Biochim Biophys Acta; 2009 Oct; 1788(10):2259-66. PubMed ID: 19595666
[TBL] [Abstract][Full Text] [Related]
13. Targeted delivery of antisense oligodeoxynucleotide and small interference RNA into lung cancer cells.
Li SD; Huang L
Mol Pharm; 2006; 3(5):579-88. PubMed ID: 17009857
[TBL] [Abstract][Full Text] [Related]
14. Dicer-labile PEG conjugates for siRNA delivery.
Kow SC; McCarroll J; Valade D; Boyer C; Dwarte T; Davis TP; Kavallaris M; Bulmus V
Biomacromolecules; 2011 Dec; 12(12):4301-10. PubMed ID: 22053777
[TBL] [Abstract][Full Text] [Related]
15. Direct Pharmacological Inhibition of β-Catenin by RNA Interference in Tumors of Diverse Origin.
Ganesh S; Koser ML; Cyr WA; Chopda GR; Tao J; Shui X; Ying B; Chen D; Pandya P; Chipumuro E; Siddiquee Z; Craig K; Lai C; Dudek H; Monga SP; Wang W; Brown BD; Abrams MT
Mol Cancer Ther; 2016 Sep; 15(9):2143-54. PubMed ID: 27390343
[TBL] [Abstract][Full Text] [Related]
16. Characterization of cationic liposome formulations designed to exhibit extended plasma residence times and tumor vasculature targeting properties.
Ho EA; Ramsay E; Ginj M; Anantha M; Bregman I; Sy J; Woo J; Osooly-Talesh M; Yapp DT; Bally MB
J Pharm Sci; 2010 Jun; 99(6):2839-53. PubMed ID: 20091826
[TBL] [Abstract][Full Text] [Related]
17. Enhanced Anti-Tumor Efficacy of Lipid-Modified Platinum Derivatives in Combination with Survivin Silencing siRNA in Resistant Non-Small Cell Lung Cancer.
Mattheolabakis G; Ling D; Ahmad G; Amiji M
Pharm Res; 2016 Dec; 33(12):2943-2953. PubMed ID: 27528390
[TBL] [Abstract][Full Text] [Related]
18. Aerosol delivery of stabilized polyester-siRNA nanoparticles to silence gene expression in orthotopic lung tumors.
Yan Y; Zhou K; Xiong H; Miller JB; Motea EA; Boothman DA; Liu L; Siegwart DJ
Biomaterials; 2017 Feb; 118():84-93. PubMed ID: 27974266
[TBL] [Abstract][Full Text] [Related]
19. Surface functionalized cationic lipid-DNA complexes for gene delivery: PEGylated lamellar complexes exhibit distinct DNA-DNA interaction regimes.
Martin-Herranz A; Ahmad A; Evans HM; Ewert K; Schulze U; Safinya CR
Biophys J; 2004 Feb; 86(2):1160-8. PubMed ID: 14747350
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive evaluation of canonical versus Dicer-substrate siRNA in vitro and in vivo.
Foster DJ; Barros S; Duncan R; Shaikh S; Cantley W; Dell A; Bulgakova E; O'Shea J; Taneja N; Kuchimanchi S; Sherrill CB; Akinc A; Hinkle G; Seila White AC; Pang B; Charisse K; Meyers R; Manoharan M; Elbashir SM
RNA; 2012 Mar; 18(3):557-68. PubMed ID: 22294662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
